City

Berlin (1)

London (1)

Salvador (1)

Condition

Multiple Myeloma Stage I (3)

Multiple Myeloma Progression (1)

Multiple Myeloma Stage II (1)

Multiple Myeloma Stage III (1)

Multiple Myeloma With Failed Remission (1)

Multiple Myeloma in Relapse (1)

Overall Status

Recruiting (1)

Terminated (1)

Unknown status (1)

Sign in for free

Phase

phase 3 (2)

phase 2/phase 3 (1)

Sponsor

Grupo de Estudos Multicentricos em Onco-Hematologia (1)

Lawson Health Research Institute (1)

Novartis Pharmaceuticals (1)

Collaborator

Dalhousie University (1)

Hamilton Health Sciences Corporation (1)

Niagara Health System (1)

The Ottawa Hospital (1)

Intervention

asa (1)

calcium / vitamin d (1)

cyclo thal dex daratumumab (1)

rivaroxaban (1)

zoledronic acid (1)

Study Documents

Intervention Type

drug (2)

combination product (1)

dietary supplement (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

multiple myeloma stage i

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II Trial in London (Rivaroxaban, ASA)

Recruiting

Multiple Myeloma in Relapse
+5 more

London, Ontario, Canada

London Health Sciences Centre

Oct 3, 2022

Multiple Myeloma Stage I Trial in Salvador (Cyclo Thal Dex Daratumumab)

Unknown status

Multiple Myeloma Stage I

Cyclo Thal Dex Daratumumab

Salvador, Bahia, Brazil

CEHON - Centro de Hematologia e Oncologia da Bahia

Jan 2, 2019

Multiple Myeloma Stage I Trial in Berlin (Zoledronic acid, Calcium / Vitamin D)

Terminated

Has Results

Multiple Myeloma Stage I

Zoledronic acid
Calcium / Vitamin D

Berlin, Germany

Novartis Investigative Site

Apr 5, 2012